Clinical Trials Directory

Trials / Completed

CompletedNCT00598390

PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP

PET Test/Retest Brain Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
19 (actual)
Sponsor
National Institute of Mental Health (NIMH) · NIH
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The purpose of this protocol is to measure brain CB1 receptors in the hope to better understand how they work, so that one day we can understand how the CB1 receptors are involved in psychiatric, neurological, and behavioral disorders.

Detailed description

MePPEP is a ligand that is highly selective for the cannabinoid type 1 (CB1) receptor. This receptor is considered the most common G-coupled protein receptor in the brain (Pacher et al., 2006). The CB1 receptor is the site of action of Delta-9-tetrahydrocannbinol (THC), the active compound in marijuana, and is found primarily on the presynaptic terminals of dopaminergic, glutamatergic, GABAergic neurons (Howlett et al., 2002). The function of the CB1 receptor is not entirely clear; however, it has been implicated in several neurological and psychiatric disorders, and a selective inverse agonist, rimonabant, is currently in use in Europe for the treatment of obesity (Van Gaal et al., 2005). \[11C\]MePPEP was developed to enhance our understanding of the in vivo characteristics of the CB1 receptor (e.g., receptor density and receptor occupancy with pharmaceuticals). The purpose of this protocol is to establish an accurate method to measure CB1 receptor levels in brain by performing test/retest brain imaging studies. The results of this overall study are required to apply this PET ligand in various neurological and psychiatric disorders in the future.

Conditions

Interventions

TypeNameDescription
DRUG[11C]MePPEP

Timeline

Start date
2008-01-08
Primary completion
2013-01-22
Completion
2013-01-22
First posted
2008-01-21
Last updated
2020-04-02

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00598390. Inclusion in this directory is not an endorsement.